Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BSX 
Boston Scientific Corp (BSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BSX (5-star) is a STRONG-BUY. BUY since 26 days. Profits (-0.43%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
34 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $124.14
1 Year Target Price $124.14
| 23 | Strong Buy |
| 8 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.54% | Avg. Invested days 65 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 156.87B USD | Price to earnings Ratio 63.02 | 1Y Target Price 124.14 |
Price to earnings Ratio 63.02 | 1Y Target Price 124.14 | ||
Volume (30-day avg) 34 | Beta 0.66 | 52 Weeks Range 80.50 - 108.94 | Updated Date 08/27/2025 |
52 Weeks Range 80.50 - 108.94 | Updated Date 08/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.55% | Operating Margin (TTM) 18.63% |
Management Effectiveness
Return on Assets (TTM) 5.39% | Return on Equity (TTM) 11.55% |
Valuation
Trailing PE 63.02 | Forward PE 35.71 | Enterprise Value 169136556341 | Price to Sales(TTM) 8.48 |
Enterprise Value 169136556341 | Price to Sales(TTM) 8.48 | ||
Enterprise Value to Revenue 9.15 | Enterprise Value to EBITDA 36.4 | Shares Outstanding 1481750016 | Shares Floating 1477469372 |
Shares Outstanding 1481750016 | Shares Floating 1477469372 | ||
Percent Insiders 0.19 | Percent Institutions 93.6 |
Upturn AI SWOT
Boston Scientific Corp
Company Overview
History and Background
Boston Scientific Corp. was founded in 1979. It evolved from a division of American Hospital Supply Corporation. It grew through strategic acquisitions and internal innovation, becoming a major player in the medical device industry.
Core Business Areas
- MedSurg: Focuses on endoscopy, urology, and pelvic health products and solutions.
- Cardiology: Offers a wide range of products for interventional cardiology, including coronary stents, balloons, and guidewires.
- Neuromodulation: Develops and manufactures implantable neuromodulation systems for chronic pain and other neurological conditions.
Leadership and Structure
The CEO is Michael Mahoney. The company has a functional organizational structure with various divisions focused on specific therapeutic areas.
Top Products and Market Share
Key Offerings
- Market Share (%): 20
- Watchman FLX Left Atrial Appendage Closure (LAAC) Device: A device to prevent stroke in patients with atrial fibrillation. Market share is significant but varies geographically. Competitors include Abbott's Amulet and Johnson & Johnson's Biosense Webster. Approximately ~$1B in revenue.
- Market Share (%): 15
- Vercise Genus Deep Brain Stimulation (DBS) System: A system for managing symptoms of Parkinson's disease and essential tremor. Competitors include Medtronic and Abbott. Market share is growing. No Revenue Data Availalbe
- Market Share (%): 18
- Polarx Cryoablation System: A cryoablation system for the treatment of atrial fibrillation. Competing with Medtronic, Johnson & Johnson. Market share is growing. No Revenue Data Available.
Market Dynamics
Industry Overview
The medical device industry is characterized by high growth potential driven by an aging population, technological advancements, and increasing healthcare spending. It is heavily regulated and highly competitive.
Positioning
Boston Scientific Corp. is a leading player in the medical device industry with a diversified portfolio and a strong focus on innovation. It competes with larger, more established players in some segments and smaller, more specialized companies in others.
Total Addressable Market (TAM)
The global medical device market is estimated to be over $500 billion. Boston Scientific addresses a significant portion of this market, particularly in cardiovascular, neuromodulation, and endoscopy. The TAM for these segments are growing rapidly, and Boston Scientific is positioned to capture a good share of this TAM.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Global presence
- Established brand reputation
- Strong distribution network
Weaknesses
- High debt levels
- Dependence on acquisitions for growth
- Exposure to product liability litigation
- Vulnerability to regulatory changes
- Integration challenges with acquired companies
Opportunities
- Expanding into emerging markets
- Developing new technologies in areas such as robotics and digital health
- Acquiring smaller, innovative companies
- Partnering with healthcare providers to improve patient outcomes
- Increased healthcare spending
Threats
- Increasing competition from established and emerging players
- Pricing pressures from healthcare providers and payers
- Product recalls and safety concerns
- Economic downturns affecting healthcare spending
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MDT
- ABT
- JNJ
Competitive Landscape
Boston Scientific Corp. competes with larger, more established companies such as Medtronic and Abbott, as well as smaller, more specialized companies. It differentiates itself through its diversified portfolio, strong R&D capabilities, and global presence.
Major Acquisitions
Apollo Endosurgery
- Year: 2023
- Acquisition Price (USD millions): 615
- Strategic Rationale: Expands Boston Scientific's endoscopy portfolio and capabilities in the growing bariatric surgery market.
Growth Trajectory and Initiatives
Historical Growth: Boston Scientific Corp. has grown both organically and through acquisitions. Historical growth rates have varied depending on the segment and macroeconomic conditions.
Future Projections: Analysts project continued revenue growth, driven by new product launches and expansion into emerging markets. Profitability is expected to improve, but debt management will be critical.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies with complementary technologies, investments in R&D, and expansion into emerging markets.
Summary
Boston Scientific is a strong medical device company with a diverse portfolio and good growth prospects. Key strengths include innovative products and global reach. However, a large amount of debt and intense competition are major concerns, especially increasing pricing pressures from healthcare providers and payers. They need to focus on managing debt and gaining/maintaining pricing power.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Industry News and Publications
- Market Research Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and due diligence. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boston Scientific Corp
Exchange NYSE | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1992-05-18 | Chairman, President & CEO Mr. Michael F. Mahoney | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.bostonscientific.com |
Full time employees 53000 | Website https://www.bostonscientific.com | ||
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.